Results 281 to 290 of about 123,443 (349)

Effects of cannabidiol in alcohol use disorder patients with and without co‐occurring post‐traumatic stress disorder: Tolerability but no evidence for efficacy in two randomized proof‐of‐concept trials

Alcohol, Clinical and Experimental Research, Volume 50, Issue 1, January 2026.
Two small placebo‐controlled trials evaluated the effects of cannabidiol (CBD) in patients with alcohol use disorder (AUD), with and without co‐occurring post‐traumatic stress disorder (PTSD). CBD was rapidly absorbed and generally well tolerated in dosages of up to 1200 mg/day. Both treatment groups showed large reductions in drinking.
Michael P. Bogenschutz, Esther Blessing, Danielle Dgheim, Dayeon Cho, Jun Zhang, Eugene M. Laska, Charles R. Marmar   +6 more
wiley   +1 more source

Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products. [PDF]

Toxicol Rep
Lin K, Sun Y, Raghu R, Suharu P, Effah F, Rahman I.   +5 more
europepmc   +1 more source

JWH-182: a safe and effective synthetic cannabinoid for chemotherapy-induced neuropathic pain in preclinical models [PDF]

Leontina-Elena Filipiuc, Ioana Creangă-Murariu, Bogdan-Ionel Tamba, Daniela Carmen Ababei, Răzvan-Nicolae Rusu, Gabriela Dumitriţa Stanciu, Raluca Ştefănescu, Mitică Ciorpac, Andrei Szilagyi, Raluca Gogu, Silviu-Iulian Filipiuc, Ivona-Maria Tudorancea, Carmen Solcan, Teodora Alexa‐Stratulat, Carmen Marinela Cumpăt, Doina-Clementina Cojocaru, Veronica Bild   +16 more
openalex   +1 more source

Selective anti-cancer effects of cannabidiol and Δ9-tetrahydrocannabinol via PI3K/AKT/mTOR inhibition and PTEN restoration in ovarian cancer cells. [PDF]

Front Pharmacol
Tong S, Loilome W, Namwat N, Klanrit P, Wangwiwatsin A, Win ZZ, Koyabuth P, Chumworathayi B.   +7 more
europepmc   +1 more source

Use of oral neuromodulators in chronic pelvic painNumber 8 - 2025. [PDF]

Rev Bras Ginecol Obstet
Poli OB, Silva JCRE, Petta CA, Lino CAPC, Schor E, Ribeiro HSAA, Nogueira J, da Cunha JSL, França MC, Carneiro MM, de Oliveira MAP, Tcherniakovsky M, Abrão MS, Dib RP, Quintairos RA, Podgaec S, Pearce S.   +16 more
europepmc   +1 more source

Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

Clinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype‐specific adverse events and pharmacokinetic profiles of cannabidiol, 7‐OH cannabidiol (an active metabolite), and 7‐COOH ...
Jumar Etkins, Gerald C. So, Jessica Bo Li Lu, Sachiko Koyama, Debora L. Gisch, Ricardo Melo Ferreira, Ying‐Hua Cheng, Kelsey McClara, Joshua Jun, Matthew Miller, Zeruesenay Desta, Michael T. Eadon   +11 more
wiley   +1 more source

From deficiency to toxicity: Magnesium increases cannabinoid and terpene production in cannabis plants. [PDF]

J Cannabis Res
Morad D, Bernstein N.
europepmc   +1 more source

Cannabinoid overrides triggers of GABAergic plasticity in vestibular circuits and distorts the development of navigation

Wei Shi, Kenneth Lap‐Kei Wu, Mengliu Yang, Francisco Paulo De Nogueira Botelho, Oscar Wing Ho Chua, Huijing Hu, Ka‐Pak Ng, Ulysses Tsz-Fung Lam, Kin-Wai Tam, Chun‐Wai Ma, Daisy Kwok-Yan Shum, YS Chan   +11 more
openalex   +1 more source

Is Addiction Research Addicted to Artificial Intelligence? Mapping the Intersection of Artificial Intelligence, Substance Use and Mental Health Through a Bibliometric Analysis

Drug and Alcohol Review, Volume 45, Issue 1, January 2026.
ABSTRACT Issues From extracting insights from large‐scale, multimodal data to prevention and support, there is growing interest in the applications and implications of recent advances in Artificial Intelligence (AI) within the fields of addiction, substance use and mental health, which we refer to as ASUM.
Loïs Vanhée, Simone Scarpa
wiley   +1 more source

Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes. [PDF]

Front Pharmacol
Sermsaksasithorn P, Nopsopon T, Samuthpongtorn C, Chotirosniramit K, Pongpirul K.   +4 more
europepmc   +1 more source